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ABSTRACT
Background: Indinavir is widely used for the treatment of human immunodeficiency virus (HIV) infection. It is known to cause hyperglycemia or 
insulin resistance and hyperlipidemia.
Aim and Objectives: To study the effect of Swertia chirata leaf extract with metformin and pioglitazone on indinavir treated rats.
Methods: Swiss albino rats were divided into five Groups of six animals each. All the groups (except control) were treated with indinavir 
216 mg/kg (oral) for 15 days. Group I (control) received normal saline (oral) from day 1 to day 15, Group II received indinavir 216 mg/kg (oral), 
Group III received S. chirata plant extract 500 mg/kg (oral) from day 8 to day 15, Group IV received pioglitazone 4 mg/kg (oral) from day 8 to day 15, 
and Group V received metformin 180 mg/kg (oral) from day 8 to day 15. The biochemical parameters such as serum glucose, insulin, and lipid levels 
were measured on day 15. Results were analyzed using one-way analysis of variance followed by Bonferroni’s multiple comparison test.
Results: Indinavir (216 mg/kg) treated rats showed a significant (p<0.05) increase in glucose and insulin levels and also altered lipid levels. This 
indicates indinavir produces diabetic-like state in rats. S. chirata extract (500 mg/kg) decreases glucose and insulin levels and also improves lipid 
levels the effect is almost similar to metformin and pioglitazone.
Conclusion: Indinavir causes elevated glucose, insulin and lipid levels, so care must be taken while prescribing indinavir for HIV patients. Treatment 
with S. chirata extract improved the altered glucose, insulin, and lipid profile in indinavir treated rats.
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INTRODUCTION
Antiretroviral agents prevent the progression of disease which is 
caused by human immunodeficiency virus (HIV). Therapy includes a 
combination of minimum three drugs and available regimens forms 
more than 1100 combinations. The unique property of these drugs 
is need for lifelong administration to control virus replication and to 
prevent the development of drug resistance. The contribution of PI’s 
is considered to a great extent in the prevention of HIV-associated 
morbidity and mortality over many years and remain a cornerstone of 
HAART. Long-term therapy with PI’s is found to cause insulin resistance 
(IR) and hyperglycemia, epidemic Type-2 diabetes mellitus and 
other complications such as hyperglycemia, hypercholesterolemia or 
lipodystrophy. PI’s found to produce long-term suppression of viremia, 
increase in CD4 lymphocyte counts, reduced disease progression, and 
decrease in mortality, the benefits and toxicity of this drug needs to be 
balanced [1-4].
This class of drug found to be very effective but they also found to 
be associated with metabolic changes that greatly increase lifetime 
risk [5,6]. Among these, one of the important metabolic changes is 
alteration of normal glucose-insulin homeostasis which remains 
particularly prevalent and alarming clinical change in affected 
patients. IR, impaired glucose tolerance, and Type-II diabetes mellitus 
are the most common in patients receiving HAART, especially with 
PI’s [7-9].
The occurrence of DM is four-fold higher in HIV-infected patients 
receiving HAART compared to HIV-seronegative men [10]. Lifespan 
of HIV infected patients is increased due to availability advanced 
antiretroviral drugs. HIV-infected patients can lead a normal life but 
there is an increased chance of risk from noninfectious caused such as 
cardiovascular disease and diabetes [11-13].
Pioglitazone act by increasing insulin sensitivity in peripheral tissue 
and it increases glucose transport into muscle and adipose tissue. 
It also activates the genes that regulate fatty acid metabolism in 
peripheral tissue [14]. Metformin is known as insulin sensitizer; that 
is, it increases glucose uptake and utilization by target tissues, thereby 
decreasing IR. It requires insulin for its action but does not promote 
insulin secretion [15,16].
Swertia chirata belongs to the family of Gentianaceae. It is also known 
as Chirata, Chirayata and this is also mentioned in Charaka Samhitha a 
classical Indian medical text. Based on research, scientists confirmed 
this plant as a potential antidiabetic agent. Recent decades researchers 
also revealed its antimalarial, anti-inflammatory, antioxidative, and 
anticarcinogenic properties of this plant. Hence, we have selected it 
for this study, the effect of S. chirata leaf extract with metformin and 
pioglitazone on indinavir-treated rats.
METHODS
Raring of animals
For this study male albino Wister rats, weighing between 230 and 300 
g were used. Rats were procured from the central animal house of 
institution. The experiment protocol used for this study was approved 
by the institutional animal ethical committee [Ref.No: KSHEMA/
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IAEC/03/2013]. They were maintained under standard laboratory 
condition at temperature 23±2°C, humidity 50±10% with 12 hrs 
light/12 hrs dark cycles. Animals were maintained at polypropylene 
cages, rat pellets and water were given ad libitum.
Drugs and chemicals
Indinavir was obtained from yarrow chem products, Mumbai. 
Metformin and Pioglitazone were obtained from Mahalakshmi 
chemicals, Hyderabad. Ketamine injection was obtained from Neon 
Laboratories Limited, Mumbai.
Reagents and kits
The biochemical parameters such as glucose and lipid profile were 
measured using commercially available kits (Agappe Diagnostics Ltd, 
Kochi). To measure insulin levels the Ultra sensitive Rat insulin enzyme-
linked immunosorbent assay (ELISA) kit were obtained from Genxbio 
Health Sciences Private Limited, New Delhi.
Preparation of S. chirata leaf extract
Leaves of S. chirata were used for this study; leaves were dried at room 
temperature. Dried leaves are taken into a Soxhlet apparatus; ethanol is 
used for the process of extraction.
Phytochemical analysis
S. chirata ethanolic extract was subjected to preliminary phytochemical 
analysis for detection of major chemical constituents such as alkaloids, 
phenols, resins, tannins, terpenoid, and saponins.
Experimental design
The animals were divided into five Groups (n=6). The study was 
conducted for 15 days. A pilot study was conducted initially to 
determine dose of indinavir which causes hyperglycemia or IR and 
hyperlipidemia. At the same time, dose of antidiabetic drugs such as 
metformin and pioglitazone was determined.
Group I (control) received normal saline (oral) from day 1 to day 
15, Group II received indinavir 216 mg/kg (oral), Group III received 
S. chirata plant extract 500 mg/kg (oral) from day 8 to day 15, Group IV 
received pioglitazone 4 mg/kg (oral) from day 8 to day 15, and Group V 
received metformin 180 mg/kg (oral) from day 8 to day 15. All the 
groups (Except control) were treated with indinavir 216 mg/kg (oral) 
for 15 days. The 2% Gum acacia were used as a vehicle.
At the end of study period, i.e., on 15th day, rats were anesthetized and 
fasting blood glucose was collected by retro-orbital sinus puncture for 
estimation of biochemical parameters.
Biochemical estimation
Blood samples were centrifuged at 2000 RPM and serum was separated. 
The serum was used for the biochemical investigations. Serum glucose 
levels were measured by glucose oxidase and peroxidase (GOD-POD) 
method, triglycerides measured by glycerol phosphate oxidase-POD, 
total cholesterol (CH), high-density lipoproteins (HDL), and low-
density lipoproteins (LDL)-CH by oxidase POD (CHOD-PAP) methods. 
Very LDL (VLDL) CH was estimated using the formulas, VLDL=TG/5. 
The serum insulin levels were estimated by ELISA method using ELISA 
reader.
Oral glucose tolerance test (OGTT)
At the end of experimental period, OGTT was performed in all groups of 
rats. The 12hr fasted rats were treated with glucose solution at a dose of 
2 g/kg body weight by oral route, followed by collection of blood sample 
for analysis.
Statistical analysis
The data were presented in mean±standard error of the mean. 
Results were analyzed using one-way analysis of variance followed by 




The preliminary phytochemical analysis of S. chirata leaf extract 
showed the presence of Carbohydrate, Coumarins and Tannin. 
Biochemical parameters
In Group II rats treated with indinavir 216 mg/kg (oral) significantly 
increased Insulin, total CH, TG’s, LDL, and VLDL levels without causing 
much change in HDL levels in comparison to control group. It indicates 
that indinavir produces diabetic-like state in rats. Treatment of rats in 
Group III with ethanolic extract of S. chirata leaf extract significantly 
reduced the elevated insulin, total CH, TG’s, LDL, and VLDL levels in 
comparison Group II. There was no significant difference on insulin and 
lipid profile between the standard drugs Metformin, pioglitazone and 
with the treatment of S. chirata leaf extract on rats, as shown in Fig. 1 
and Table 1.
OGTT
It was observed that after a 2 hrs glucose load Group II shows significant 
high serum glucose levels compared to normal. In Groups III and V, the 
glucose levels were significantly less compared to Group II (Fig. 2).
Random serum glucose concentration was measured which shows 
a significant difference compared to control and treatment groups 
(Fig. 3).
DISCUSSION
Protease inhibitors are known to induce a syndrome of IR along 
with that it may also cause hyperglycemia, hyperlipidemia, and fat 
Fig. 1: 1 Effect of indinavir, Swertia chirata extract and standard 
drugs on rat serum insulin levels. Values are expressed in 
mean±standard error of the mean, *p<0.05 vs. Normal control, 
†p<0.05 vs. diabetic control
Fig. 2: Effect of indinavir, Swertia chirata extract and standard 
drugs on rat serum glucose levels
341
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 339-342
 Rajesh et al. 
redistribution. It resembles the metabolic syndrome with high risk of 
cardiovascular diseases. Many research studies were done to assess IR 
using a homeostasis model assessment of IR (HOMA-IR). The calculated 
score higher than four using HOMA-IR indicates IR. Early studies of 
insulin profile in the patients infected with HIV infection were no IR or 
hyperglycemia was observed, but clamp studies indicated the increased 
IR. Protease inhibitors can cause decrease in insulin-stimulated glucose 
transport in fat cells [16]. Patients with HIV infection must be screened 
at the beginning of HAART therapy, and later during the treatment. 
Certain professionals suggest for fasting blood glucose as a screening 
tool; others recommend OGTT which should be performed as a part of 
screening procedures [17].
The actual mechanism of IR is not well understood. IR occurs 
when normal insulin levels are no sufficient to stimulate glucose 
uptake in the insulin signaling pathway in insulin-sensitive tissues 
such as muscle, liver, and subcutaneous adipose tissue. Following 
manifestations such as hyperinsulinemia, hyperglycemia, and 
dislipidemia (hypertriglyceridemia) are seen in patients with protease 
inhibitors [18,19].
The treatment with PIs caused partial lipodystrophies in some 
reports and also found to cause DM or insulin resistance along 
with higher triglyceride and CH levels. There is also peripheral fat 
wasting, accumulation of intra-abdominal fat has been observed in 
some patients. Inhibition of hormone sensitive lipase and insulin 
induced stimulation of lipoprotein lipase would result in net increase 
of fat. Inhibition of lipogenesis and stimulation of lipolysis results in 
inappropriate increase in free fatty acids. Increased availability of free 
fatty acids would further increase hepatic triglyceride synthesis and 
increases hepatic glucose output, which causes compensatory increase 
in insulin secretion to maintain glucose uptake homeostasis. There 
are many theories suggests that PIs therapy induces DM, beside that 
there is increasing evidence that there is an increase in insulin levels 
suggesting emergence of IR [20,21].
It has been observed that PIs selectively inhibit GLUT4 activity in vitro, 
which provides an important mechanism for the development of 
IR observed in the patients with HIV infection. Whole body glucose 
disposal takes place by glucose transport, GLUT4 is expressed in tissue 
responsible for glucose disposal (skeletal/cardiac muscle and fat), and it 
is believed to be principal transporter for mediating insulin stimulated 
glucose uptake at these sites. PIs causes inhibition of GLUT4, and the 
inhibition is reversible when the treatment is stopped. PIs inhibitors 
induced IR also associated with lipodystrophy syndrome caused by 
GLUT4 inhibition. Chronic treatment of indinavir causes elevated free 
fatty acids secondarily contribute to IR, prolonged treatment may 
cause redistribution of fat and hypertriglyceridemia may also cause 
IR. Hyperinsulinism from GLUT4 inhibition may contribute to fat 
distribution [22,23].
S. chirata was known to possess antidiabetic activity since a long 
time. To study the hypoglycemic and antidiabetic role of S. chirata 
95% ethanolic extract and other four fractions were used, and the 
significant effect was produced by lowering blood sugar level [24]. 
The Swertia extract significantly decreases the CH and lipid levels. 
Phytochemical analysis was performed and the extract was known to 
contain carbohydrate, coumarins, and Tannin. The S. chirata is also 
known to contain three main phytochemicals amarogentin, mangiferin, 
and Swertia merin. Mangiferin is known to have blood glucose lowering 
property and also shows suppressive effect on lipid profile [25,26].
CONCLUSION
This study reveals that S. chiratais is effective against indinavir-induced 
hyperglycemia or IR and hyperlipidemia. S. chirata with its multiple 
beneficial effects would seem to be useful as an adjuvant with indinavir 
(protease inhibitor) on AIDS patients.
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